1-2 of 2
W. Jonathan Kell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Clinical Trials & Observations
Steven Knapper, Alan K. Burnett, Tim Littlewood, W. Jonathan Kell, Sam Agrawal, Raj Chopra, Richard Clark, Mark J. Levis, Donald Small
Journal: Blood
Blood (2006) 108 (10): 3262–3270.
https://doi.org/10.1182/blood-2006-04-015560
Published: 2006
Journal Articles

Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells

Clinical Trials & Observations Brief Report
Richard G. Goodwin, W. Jonathan Kell, Peter Laidler, C. Colin Long, Sharon D. Whatley, Mark McKinley, Michael N. Badminton, Alan K. Burnett, Geraint T. Williams, George H. Elder
Journal: Blood
Blood (2006) 107 (1): 60–62.
https://doi.org/10.1182/blood-2004-12-4939
Published: 2006